These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33723299)

  • 1. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.
    Božič Mijovski M; Malmström RE; Vene N; Antovic JP; Mavri A
    Sci Rep; 2021 Mar; 11(1):5920. PubMed ID: 33723299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation.
    Bloemen S; Zwaveling S; Douxfils J; Roest M; Kremers R; Mullier F
    Thromb Res; 2018 Nov; 171():160-166. PubMed ID: 30316961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
    Jacquemin M; Toelen J; Schoeters J; van Horenbeeck I; Vanlinthout I; Debasse M; Peetermans M; Vanassche T; Peerlinck K; van Ryn J; Verhamme P
    J Thromb Haemost; 2015 Nov; 13(11):2087-92. PubMed ID: 26347330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.
    Arellano-Rodrigo E; Fernandez-Gallego V; López-Vilchez I; Molina P; Díaz-Ricart M; Zafar MU; Badimon JJ; van Ryn J; Escolar G
    Transfusion; 2019 Jul; 59(7):2436-2445. PubMed ID: 30946491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
    Jacquemin M; Toelen J; Feyen L; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Vanassche T; Peerlinck K; Verhamme P
    Int J Lab Hematol; 2018 Aug; 40(4):442-447. PubMed ID: 29573340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
    Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
    Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
    Rosenberg L; Gerstrøm G; Nybo M
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger.
    Taune V; Skeppholm M; Ågren A; Gryfelt G; Malmström RE; Wikman A; Van Ryn J; Wallén H
    J Thromb Haemost; 2018 Dec; 16(12):2462-2470. PubMed ID: 30288934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
    Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
    Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
    Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
    Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood.
    Nadtochiy SM; Baldzizhar A; Stefanos T; Feng C; O'Leary KE; Jones-Smith KL; Angona RE; Eaton MP
    Anesth Analg; 2021 Feb; 132(2):566-574. PubMed ID: 32833714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report.
    Facchinetti R; DeGuidi G; Pitoni F; Ricci G; Lippi G
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):576-579. PubMed ID: 28362649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.